Diabetes mellitus and neurodegeneration are common diseases for which shared genetic factors are still only partly known. Here, we show that loss of the BiP (immunoglobulin heavy-chain binding protein) co-chaperone DNAJC3 leads to diabetes mellitus and widespread neurodegeneration. We investigated three siblings with juvenile-onset diabetes and central and peripheral neurodegeneration, including ataxia, upper-motor-neuron damage, peripheral neuropathy, hearing loss, and cerebral atrophy. Exome sequencing identified a homozygous stop mutation in DNAJC3. Screening of a diabetes database with 226,194 individuals yielded eight phenotypically similar individuals and one family carrying a homozygous DNAJC3 deletion. DNAJC3 was absent in fibroblasts from all affected subjects in both families. To delineate the phenotypic and mutational spectrum and the genetic variability of DNAJC3, we analyzed 8,603 exomes, including 506 from families affected by diabetes, ataxia, upper-motor-neuron damage, peripheral neuropathy, or hearing loss. This analysis revealed only one further loss-of-function allele in DNAJC3 and no further associations in subjects with only a subset of the features of the main phenotype. Our findings demonstrate that loss-of-function DNAJC3 mutations lead to a monogenic, recessive form of diabetes mellitus in humans. Moreover, they present a common denominator for diabetes and widespread neurodegeneration. This complements findings from mice in which knockout of Dnajc3 leads to diabetes and modifies disease in a neurodegenerative model of Marinesco-Sjögren syndrome.
Nonautoimmune diabetes mellitus and neurodegeneration are common disorders for which shared genetic factors are still only partly known. Monogenic forms of diabetes include neonatal diabetes (MIM 606176) and maturity-onset diabetes of the young (MIM 606391), both of which arise from mutations that primarily reduce pancreatic b cell function. 1 Although monogenic forms account for only about 1%-2% of diabetes cases, they provide unique insights into the underlying basic disease mechanisms, such as endoplasmic reticulum (ER) stress. 2, 3 Given that reduced mitigation of ER stress due to genetic mutations has been shown to cause both diabetes mellitus and multisystemic neurodegeneration (e.g., in Wolfram syndrome 1 [MIM 222300] 3, 4 ), it might present a shared mechanism linking diabetes with neurodegeneration.
Mutations leading to loss of the ER protein DNAJC3-which serves to attenuate late phases of ER stress 5 -have been shown to lead to pancreatic b cell failure and diabetes in mice. 6 However, it is still unknown whether mutations in DNAJC3 (MIM 601184; RefSeq accession number NM_006260.4) also cause disease in humans. Here, we show in two index families that loss-of-function mutations in DNAJC3 and the resulting absence of ER protein DNAJC3 lead to diabetes mellitus and multisystemic neurodegeneration. Whole-exome sequencing (WES) was performed in two affected individuals (61691 and 61695, who are subjects II.2 and II.4, respectively, in family 1 in Figure 1A ) of a consanguineous Turkish family affected by juvenile-onset diabetes and central and peripheral neurodegeneration, including early-onset ataxia, upper-motor-neuron damage, demyelinating peripheral neuropathy, neuronal hearing loss, and cerebral atrophy. This procedure and all following procedures reported in this manuscript were approved by the institutional review board of the University of Tübin-gen in Germany (reference number 598/20118O1), and proper informed consent was obtained from all subjects. After in-solution capture of exonic sequences (SureSelect Human All Exon 50 Mb Kit, Agilent Technologies), both samples were sequenced to an average of 1263 and 1733 coverage on the Illumina platform (Genome Analyzer II3 System). For sequencing statistics, see Table S1 (available online). We used the Burrows-Wheeler Aligner (version 0.5.8) for read alignment to the human reference assembly (UCSC Genome Browser hg19) and SAMtools (version 0.1.7) for detection of single-nucleotide variants and small insertions and deletions. Given the rare combination of juvenile-onset diabetes and early-onset neurodegeneration, we assumed the causative mutations to be rare and to alter the protein sequence. We therefore excluded variants present in 4,517 exomes of control individuals with unrelated phenotypes and searched for nonsynonymous variants and splice-site mutations (Table 1) . Given the autosomal-recessive pattern of inheritance, we filtered for genes harboring potential compound-heterozygous or homozygous rare variants that were predicted to be damaging by in silico prediction software tools (SIFT and PolyPhen-2). This approach left only one gene with mutations shared by both affected individuals: DNAJC3 (Table  1) . The homozygous DNAJC3 mutation c.580C>T is predicted to cause premature truncation (p.Arg194*) of more than 60% of the protein sequence ( Figure 1B ). Sanger sequencing of additional family members showed that all three affected siblings harbor the c.580C>T mutation in a homozygous state, whereas the healthy sister (subject II.1 in Figure 1A ) has two wild-type alleles. Testing of parents demonstrated that both mutations are located in trans (for electropherograms of the Sanger sequences of all pedigree members, see Figure S1 ).
To confirm the significance of DNAJC3 mutations in the pathogenesis of diabetes-neurodegeneration syndromes, we screened the German multicenter DPV (Diabetes Patienten Verlaufsdokumentation) registry, which contains 226,194 pediatric and adult individuals with diabetes from 354 treatment centers. According to the key phenotypic characteristics of the affected members of index family 1 (for a detailed description, see Table 2 and the paragraph below), we used the following clinical screening criteria: (1) b cell antibodies, (3) body mass index (BMI) below the median for age and gender, and (4) ataxia and/or hearing impairment. This filter left 35 individuals (31 with hearing impairment, two with ataxia, and two with hearing impairment and ataxia). Because the registry does not collect biomaterials, these 35 individuals were approached through their treatment centers (29 centers in total) by their local clinicians and were asked to provide a DNA sample for DNAJC3 analysis. DNA could be obtained from eight index subjects. Conventional Sanger sequencing (oligonucleotide sequences are available upon request) revealed no mutation in seven of eight subjects. In one of the two index subjects with hearing impairment and ataxia, we failed to amplify exons 6À12 by PCR, whereas PCR amplification delivered the expected DNA fragments for exons 1-5 in the same sample and for exons 1-12 in control samples, suggesting a potential deletion affecting exons 6-12. Breakpoints of the expected deletion were characterized by PCR and a primer-walking approach and were confirmed by Sanger sequencing ( Figure 1B ). This 72 kb homozygous deletion was also identified in the affected sibling (subject II.2 of family 2, Figure 1A ) and was heterozygous in the parents (subjects I.1 and I.2 of family 2, Figure 1A) .
To delineate the phenotypic and mutational spectrum and the genetic variability of DNAJC3, we screened a total of 8,603 exomes (4, Table S2 and Figure S2 ). Apart from our index family 1, we did not identify any other family carrying two predicted loss-of-function variants in DNAJC3. Taken together, these findings suggest the following notion: although biallelic loss-of-function mutations in DNAJC3 cause diabetes and a multisystemic combination of ataxia, peripheral neuropathy, upper-motor-neuron disease, and hypacusis, they do not seem to be associated with only one of these features or a small subset of them. Next, we analyzed the overall occurrence of DNAJC3 variants to determine the genetic variability of DNAJC3 (same filters as above, but no inheritance filter). In 8,603 exomes, we identified 56 alleles with rare DNAJC3 variants, consisting of 41 unique variants (one stop [c.580C>T from index family 1], one frameshift, and 39 missense; see Table S3 ). This observation demonstrates that truncating variants in DNAJC3 are a very rare event (2 out of 17,206 alleles) and that genetic variability of DNAJC3 is low overall (56 events out of 17,206 alleles). This notion receives further independent support from the Residual Variation Intolerance Score (RVIS), which is based on the 6,500 exomes from NHLBI ESP6500. 8 This score provides a measure of the departure from the (genome-wide) average number of common functional mutations found in genes with a similar amount of mutational burden (RVIS ¼ 0 when the gene has an average number of common functional variants given its total mutational burden, RVIS < 0 when the gene has less common functional variation than predicted, and RVIS > 0 when the gene has more).
8
DNAJC3 yields a RVIS of À0.47, ranking it among the 23% most intolerant of human genes. 8 Genes such as DNAJC3, which are more intolerant of functional genetic variation, have been shown to be significantly more likely than other genes to harbor mutations that cause Mendelian diseases.
DNAJC3 acts as co-chaperone of BiP (immunoglobulin heavy-chain binding protein), a major ER-localized member of the HSP70 family of molecular chaperones, which reversibly bind to contiguous segments of hydrophobic amino acids exposed in unfolded lumenal proteins to impede aggregation and promote adequate folding.
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DNAJC3 is located in virtually all tissues in mice and humans and has especially high levels in the pancreas and liver. 10 In mice, loss of DNAJC3 leads to hyperglycemia and glucosuria associated with increasing apoptosis of pancreatic b cells and reduced insulin levels. 6 To validate Two NSVs predicted to be damaging and present in both
At least two lossof-function alleles
Nonsynonymous variants (NSVs) include missense, nonsense, stop-loss, and splice-site mutations and insertions and deletions. Variants were predicted to be damaging by at least one out of three software predictions (SIFT, PolyPhen-2, and MutationTaster).
The American Journal of Human Genetics 95, 689-697, December 4, 2014 691 the predicted loss-of-function character of the identified mutations in both families, we analyzed DNAJC3 in fibroblasts by immunoblotting. Neither full-length nor truncated DNAJC3 was detected in the affected individuals, whereas the two heterozygous parents showed normal protein levels (Figure 2 ). Given the well-established function of DNAJC3 in the downregulation of ER-associated proteins involved in the initial ER stress response, as well as the histopathological changes observed in some DNAJC3-deficient cell types, 6 we investigated the ER morphology in fibroblasts from our individuals with DNAJC3 loss of function. No changes in ER morphology were observed by electron microscopy ( Figure S3 ). This is in line with the previous finding that histological changes associated with the absence of DNAJC3 can be found only in some tissues (e.g., pancreatic islets), but not in others (e.g., pancreatic acini or other pancreatic parenchyma). 6 We analyzed protein trafficking through the secretory pathway in cell lines from subjects with homozygous DNJAC3 mutations and healthy control individuals by monitoring the secretion of Gaussia princeps luciferase into the culture medium. 12 Induction of ER stress by thapsigargin (an inhibitor of the ER Ca 2þ ATPase) or tunicamycin or glucose deprivation (both of which interfere with N-linked protein glycosylation) resulted in impaired secretion in mutant and control cells. No significant differences were noted through induction or recovery from ER stress ( Figure S4 ), indicating intact protein secretion in fibroblasts. In addition, we analyzed subjects' fibroblasts for a difference in ER calcium leakage. It has been shown for HeLa cells that a loss of BiP function leads to increased ER calcium leakage, as does replacement of BiP by an altered BiP variant, which cannot productively interact with its HSP40 co-chaperones. 13 However, no increased ER calcium leakage was observed ( Figure S5 ). Taken together, these experiments again point to the fact that fibroblasts might not be the most appropriate tissue for testing for DNAJC3-related ER stress and calcium leakage, most likely because of their low secretory activity and/or the compensatory mechanisms that are active in the affected subjects. However, no other tissue (e.g., pancreatic b cells or neurons) was available for testing. We aggregated clinical, electrophysiological, and imaging data from all five affected subjects belonging to the two index families affected by DNAJC3 loss-of-function mutations. Before identification of the DNAJC3 mutations, the phenotype in family 1 was clinically classified as a mitochondriopathy, and the phenotype in family 2 was classified as an atypical Shwachman-Bodian-Diamond syndrome (MIM 260400). All five affected subjects presented with young-onset diabetes melllitus diagnosed between 10 and 20 years of age, showed increased HbA1c levels (6.9%-12.1%), and received insulin treatment (Table 2) . IA-2 antibodies were absent in all five subjects, and GAD2 antibodies were present in four of five subjects (Table 2 ). C-peptides-which reflect the degree of residual pancreatic b cell function-were assessed in fasting serum and upon response to standardized intravenous application with 1 mg of glucagon 13 (Table S4) . Residual endogenous insulin secretion was present in all subjects, and secretion could be stimulated by glucagon (both are characteristic of most monogenic forms of diabetes 14 ). However, all subjects showed an at least relative deficit in insulin secretion, given that fasting C-peptide levels were low in absolute levels and/or in relation to the actual glucose levels and HbA1c levels (Table S4 ). Fasting C-peptide levels were in the same low range as reported for other monogenic forms of diabetes (between 100 and 700 pmol/l 14 ). The presence of residual endogenous insulin stimulation by glucagon in subjects with >3 years of diabetes history and the absence of autoimmune antibodies clearly argues against a diabetes mellitus type 1.
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All subjects exhibited multisystemic central and peripheral neurodegeneration. This included early-onset ataxia of combined cerebellar and afferent origin (age of onset ¼ 2-34 years) and sensorimotor peripheral neuropathy predominantly of the demyelinating type (Table 2) , which was observed even in the subject with the most recent disease onset of 6 months earlier (subject II.2 in family 2). Four of five (80%) individuals developed early-onset sensorineural hearing loss (range of onset ¼ 2-27 years), and two of five (40%) showed pyramidal tract signs (Table 2) . Cognitive screening by the Mini-Mental State Examination 16 in family 1 revealed an isolated cognitive deficit in Figure 2 . Immunoblot of DNAJC3
The immunoblot shows the absence of DNAJC3 in all affected subjects (with blue IDs) of both families, whereas the two heterozygous parents (with black IDs) of the siblings in family 2 showed normal protein levels. Immunoblot analysis was performed as described previously. 11 DNAJC3 antibody (rabbit, Cell Signaling Technology) was used at 1:1,000. b-actin antibody (Sigma-Aldrich) was used at 1:10,000. backward calculation of serial sevens, suggesting partial cerebrocortical dysfunction. All five affected subjects from the two index families had a below-average body weight (four were below the third percentile, and one was at the tenth percentile) and a below-normal BMI (one was below the third percentile, one was below the tenth percentile, and three were below the 50 th percentile), whereas both body weight and BMI were above average in the healthy sister (II.1) from family 1 (each were between the 75 th and 90 th percentiles; Table 2 ; Figure 3H ). All five affected subjects also showed a remarkably short body stature (four were below the third percentile, and one was at the 25 th percentile; for an example, see Figure 3H ), suggesting that it is highly likely that this is also part of the phenotype associated with DNAJC3 mutations. However, because body stature was also below average in the healthy sister (II.1) from family 1, future studies are warranted to confirm this feature. MRI available for index subjects II.2 (61691) of family 1 and II.1 (66050) of family 2 revealed generalized supra-and infratentorial atrophy pronounced in the cervical cord, cerebellar vermis, cerebellar hemispheres, and midbrain in both subjects and in the pre-and postcentral gyrus, crus cerebri, pons, and medulla in subject II.2 ( Figure 3 ). Subject II.1 (66050) of family 2 also showed several small T2 hyperintense lesions without contrast enhancement bilaterally in frontoparietal and periventricular regions ( Figure 3G ).
Dnajc3 knockout causes gradual onset of hyperglycemia and glucosuria associated with increasing apoptosis of pancreatic b cells in mice, thus mimicking disease processes in type 1 and late-stage type 2 diabetes. 6 Our findings demonstrate that-analogous to the mouse model-homozygous DNAJC3 loss-of-function mutations cause young-onset diabetes in humans. Moreover, like Dnajc3-knockout mice, 6 humans with DNAJC3 loss-offunction mutations also show a lower body weight, probably because of less body fat. 6 Our findings also reveal that the absence of DNAJC3 is associated not only with diabetes mellitus but also with widespread neurodegeneration (which was not studied in detail in the Dnajc3-knockout mice 6 ). It has already been shown for mutations in other genes encoding ER-localized BiP co-chaperones that they can lead to multisystemic neurodegeneration. For example, mutations in SIL1 lead to Marinesco-Sjögren syndrome (MSS [MIM 248800]), a multisystemic syndrome including early-onset ataxia, cognitive deficits, short stature, and pyramidal tract signs, [17] [18] [19] thus mirroring main features of the phenotype associated with DNAJC3 mutations. Both genes not only are linked phenotypically but also interact on a molecular level. Within the regulation of the BiP ATP-ADP cycle, DNAJC3 and SIL1 have opposing functions-loss of DNAJC3 has been shown to ameliorate cerebellar Purkinje cell death and ataxia in SIL1 À/À mice. Dysfunctions in the regulation of ER stress might thus serve as a common pathway linking diabetes mellitus and neurodegeneration. It has already been shown for mutations in other genes involved in the regulation of ER stress that they can lead to monogenic diabetes mellitus and multisystemic neurodegeneration, e.g., for mutations in the gene encoding ER-localized transmembrane protein WFS1. Inter alia, it interacts with SIL1 (red circles), a nucleotide exchange factor, to restore adequate folding of misfolded proteins. An overwhelming load of misfolded proteins requires more of the available BiP to bind to the exposed hydrophobic regions of these misfolded proteins. To meet this requirement, BiP dissociates from ER-transmembrane sensors, such as PERK (blue circles). The oligomerization of PERK and the consequent autophosphorylation of the free luminal domain lead to the activation of PERK. The activated cytosolic domain of PERK causes translational attenuation by directly phosphorylating the a subunit of the regulating initiator of the mRNA translation machinery, eIF-2a (blue boxes). This attenuation of translation further reduces the stress induced by misfolded proteins. Several mutations in genes encoding proteins of these UPR pathways are well established in human diseases. Mutations in EIFKA3, encoding PERK, cause WRS, which is characterized by young-onset nonautoimmune insulin-requiring diabetes, skeletal dysplasia, and short stature and thereby resembles several hallmarks of the DNAJC3-deficiency phenotype. Defects in SIL1 cause MSS. 18, 19 Clinical manifestations of MSS include early-onset cerebellar ataxia and short stature, thus also mirroring hallmarks of DNAJC3 disease.
The American Journal of Human Genetics 95, 689-697, December 4, 2014 695 MSS. [17] [18] [19] Clinical manifestations of MSS include earlyonset ataxia and short stature, thus again mirroring several features of the DNAJC3-deficiency phenotype. In summary, we have identified DNAJC3 mutations as a cause of monogenic juvenile-onset diabetes combined with early-onset multisystemic neurodegeneration. DNAJC3 plays a crucial role in ER protein folding and the UPR, thus adding evidence that dysfunctions in regulation of ER stress might serve as a common pathway linking diabetes mellitus and neurodegeneration. DNAJC3 might be linked to neurodegeneration in other ER-stress-induced and UPR diseases (e.g., Wolfram syndrome 1, WRS, and MSS) not only on a phenotypic level but also on a molecular level. We screened a total of 8603 exomes for potential homozygous or compound heterozygous variants in DNAJC3 using the following filter criteria:
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low frequency in public databases (minor allele frequency [MAF] in NHLBI ESP6500 < 1%), and genotype quality GQ > 35. We identified three families. None of them was considered to be pathogenic. 1. The p.Asp69Glu variant was predicted to be benign by several in silico software predictions (PolyPhen2, SIFT), and this family with mitochondrial complex I deficiency carried a strong mutation in the complex I deficiency ACAD9 gene, as published elsewhere 4 . 2. The p. Glu354Gln variant (rs59892430) was predicted to be possibly damaging by PolyPhen 2 and SIFT, but it was relatively frequent in control databases (MAF 0.6%) and, most importantly, did not cosegregate with disease (see supplement 4 for details). 3.
The p.Ala214Val yielded contradictory predictions by the in silico software predictions (PolyPhen2: benign; SIFT: damaging 
